Merck KGaA

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced research from Company-sponsored, investigator-sponsored, and collaborative studies — including two oral and two mini-oral presentations — at this year's World Conference on Lung Cancer, September 8-14, 2021, and the European Society for Medical Oncology (ESMO) Congress, September 16-21, 2021. “Analyses presented from ongoing and completed trials at both of these meetings have the potential to m

Merck to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021

MELBOURNE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix', the ‘Company') today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany, to conduct combination studies with one of Merck KGaA, Darmstadt, Germany's investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix's TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck KGaA, Darmstadt, Germany announced in August 2019.1

Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies

CORSIER-SUR-VEVEY, Switzerland--(BUSINESS WIRE)--Merck, a leading science and technology company, today held a ceremony celebrating the topping-out of its Biotech Development Center currently under construction in Corsier-sur-Vevey, Switzerland. This investment of €250 million, previously announced in January 2020, will help to sustainably secure capacity and high agility to deliver clinical trial material, contribute to accelerated development timelines of new biological entities, and address

Merck Celebrates Key Milestone in Construction of Biotech Development Center in Switzerland

This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?

Immutep Ltd

Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT-005 trial in patients with solid tumors. The trial will evaluate the feasibility, safety, and efficacy of Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with bintrafusp alfa (M7824).

Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced 40 abstracts, including seven oral presentations and seven poster discussions, from Company- and investigator-sponsored studies (ISS) and external collaborations, representing the Company's innovative oncology portfolio will be presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2021. “Important new anal

Data from Merck's Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine tablets), which may contribute to their ability to fight infections and develop protective antibodies from vaccines. The data were presented at the 2021 American Academy of Neu

Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company's DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide. Results from a Phase II proof-of-concept study conducted by the

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

News for Merck KGaA Stock (MKKGY)